- Home
- LNKS vs IMUX Comparison
LNKS vs IMUX Comparison
Compare LNKS & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKS
- IMUX
- Stock Information
- Founded
- LNKS 1995
- IMUX 2016
- Country
- LNKS Malaysia
- IMUX United States
- Employees
- LNKS N/A
- IMUX N/A
- Industry
- LNKS
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- LNKS
- IMUX Health Care
- Exchange
- LNKS NYSE
- IMUX Nasdaq
- Market Cap
- LNKS 113.9M
- IMUX 100.0M
- IPO Year
- LNKS 2024
- IMUX N/A
- Fundamental
- Price
- LNKS $8.59
- IMUX $1.00
- Analyst Decision
- LNKS
- IMUX Strong Buy
- Analyst Count
- LNKS 0
- IMUX 6
- Target Price
- LNKS N/A
- IMUX $12.67
- AVG Volume (30 Days)
- LNKS 507.4K
- IMUX 853.7K
- Earning Date
- LNKS 01-01-0001
- IMUX 02-20-2025
- Dividend Yield
- LNKS N/A
- IMUX N/A
- EPS Growth
- LNKS N/A
- IMUX N/A
- EPS
- LNKS N/A
- IMUX N/A
- Revenue
- LNKS $4,754,489.00
- IMUX N/A
- Revenue This Year
- LNKS N/A
- IMUX N/A
- Revenue Next Year
- LNKS N/A
- IMUX N/A
- P/E Ratio
- LNKS N/A
- IMUX N/A
- Revenue Growth
- LNKS N/A
- IMUX N/A
- 52 Week Low
- LNKS N/A
- IMUX $0.97
- 52 Week High
- LNKS N/A
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- LNKS N/A
- IMUX 34.82
- Support Level
- LNKS N/A
- IMUX $1.02
- Resistance Level
- LNKS N/A
- IMUX $1.18
- Average True Range (ATR)
- LNKS 0.00
- IMUX 0.08
- MACD
- LNKS 0.00
- IMUX -0.02
- Stochastic Oscillator
- LNKS 0.00
- IMUX 0.00
About LNKS LINKERS INDUSTRIES LIMITED
Linkers Industries Ltd is a company which acts as a manufacturer and a supplier of wire, cable harnesses with their manufacturing operations in Malaysia. Wire/cable harness refers to an assembly of wires/cables bound together with straps, cable ties and electrical tapes to transmit signals or electrical power. Company works closely with customers in each stage of a product's life cycle, including design, prototyping and production. Geographically company provides services in Thailand, Malaysia, Switzerland, United States of America, and many others, maximum revenue gained from Thailand.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.